BUSINESS

Hims & Hers Shares Plunge as Costly Weight-Loss Push Squeezes Margins

▪

Read, Watch or Listen

Media Bias Meter

Sources: 8

Center 100%

Sources: 8

Hims & Hers Health Inc. shares fell nearly 7% in premarket trading on Tuesday, August 11, 2026, following the release of its second-quarter financial results. The drop came as investors focused on shrinking profit margins and a wider-than-expected quarterly loss, which overshadowed strong subscriber growth and an upgraded full-year revenue forecast. For the second quarter, Hims & Hers reported revenue of $753 million, marking a 40% increase compared to the same period in the previous year and exceeding Wall Street consensus estimates. The telehealth platform added more than 300,000 net new subscribers during the quarter, bringing its total global subscriber base to nearly 3 million. Despite the top-line beat, the company posted a net loss of $86 million, translating to an adjusted loss of $0.37 per share. This significantly missed analyst expectations, which had anticipated a much smaller loss. Operating cash flow dropped to negative $36 million, while free cash flow stood at negative $68 million for the quarter. Management attributed the widening loss and margin compression to an aggressive corporate push into branded GLP-1 weight-loss medications, testosterone therapy, and international expansion, notably through the integration of overseas acquisitions like Eucalyptus. Gross margin declined to 64%, dropping roughly 6 percentage points sequentially on an adjusted basis, as lower-margin product lines and international markets scaled up faster than traditional offerings. Morningstar analyst Keonhee Kim noted that while the subscriber expansion remained robust, it was not enough to offset the persistent downward pressure on gross margins. In response to strong underlying demand, Hims & Hers raised its full-year 2026 revenue guidance to a range of $3.1 billion to $3.3 bil

Prepared by Christopher Adams and reviewed by editorial team.

Timeline of Events

On January 15, 2025, Hims launched new weight loss medical services.
On June 10, 2026, analysts predicted strong telemedicine revenue growth.
On July 1, 2026, international expansion efforts commenced across Europe.
On August 11, 2026, Hims reported second quarter financial results.
On August 11, 2026, company shares dropped seven percent today.
On August 11, 2026, executives raised full year revenue guidance.
On September 1, 2026, investors will evaluate third quarter recovery.
On October 15, 2026, new telehealth regulatory reviews commence nationally.
On November 15, 2026, market analysts expect updated spending reports.
On January 15, 2027, annual financial statements disclose full profitability.

News Intelligence

Hims shareholders experienced sudden stock declines following disappointing earnings reports.
Telehealth providers may reevaluate heavy investments into weight loss medications.
Retail investors, digital health subscribers, and company executive leadership teams.
Monitor official corporate quarterly filings and verified financial market updates.